Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.
Symbyax is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of about $82 million in the United States, based on IMS sales data.
For comments and feedback: editorial@rttnews.com